{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:39:32Z","timestamp":1793299172419,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-05111-9","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:13:51Z","timestamp":1781151231000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Empagliflozin versus dapagliflozin for kidney outcomes in stage 3 chronic kidney disease: a propensity score-matched multi-center cohort study"],"prefix":"10.1186","volume":"27","author":[{"given":"Joyita","family":"Bharati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"5111_CR1","doi-asserted-by":"publisher","unstructured":"Upadhyay A. SGLT2 inhibitors and kidney protection: mechanisms beyond tubuloglomerular feedback. Kidney360. 2024;5:771-82. https:\/\/doi.org\/10.34067\/KID.0000000000000425.","DOI":"10.34067\/KID.0000000000000425"},{"key":"5111_CR2","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease","year":"2024","unstructured":"Kidney Disease. Improving Global Outcomes CKDWG: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105:S117\u2013314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018.","journal-title":"Kidney Int"},{"key":"5111_CR3","doi-asserted-by":"publisher","unstructured":"Adhikari R, Jha K, Dardari Z, Heyward J, Blumenthal RS, Eckel RH, et al. National trends in use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists by cardiologists and other specialties, 2015 to 2020. J Am Heart Assoc. 2022;11:e023811. https:\/\/doi.org\/10.1161\/JAHA.121.023811.","DOI":"10.1161\/JAHA.121.023811"},{"key":"5111_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"E-KCG The","year":"2023","unstructured":"The E-KCG, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388:117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","journal-title":"N Engl J Med"},{"key":"5111_CR5","doi-asserted-by":"publisher","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436-1446. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","DOI":"10.1056\/NEJMoa2024816"},{"key":"5111_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jphs.2016.02.003","volume":"130","author":"A Tahara","year":"2016","unstructured":"Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. J Pharmacol Sci. 2016;130:159\u201369. https:\/\/doi.org\/10.1016\/j.jphs.2016.02.003.","journal-title":"J Pharmacol Sci"},{"key":"5111_CR7","doi-asserted-by":"publisher","unstructured":"Modzelewski KL, Pipilas A, Bosch NA. Comparative outcomes of empagliflozin to dapagliflozin in patients with heart failure. JAMA Netw Open. 2024;7:e249305. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.9305.","DOI":"10.1001\/jamanetworkopen.2024.9305"},{"key":"5111_CR8","doi-asserted-by":"publisher","first-page":"5915","DOI":"10.2147\/IJGM.S366943","volume":"15","author":"Z Hao","year":"2022","unstructured":"Hao Z. Y <>Zhang 2022 Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study. Int J Gen Med 15 5915\u20138 https:\/\/doi.org\/10.2147\/IJGM.S366943.","journal-title":"Int J Gen Med"},{"key":"5111_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.diabres.2019.04.008","volume":"151","author":"EJ Ku","year":"2019","unstructured":"Ku EJ, Lee DH, Jeon HJ, Oh TK. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study. Diabetes Res Clin Pract. 2019;151:65\u201373. https:\/\/doi.org\/10.1016\/j.diabres.2019.04.008.","journal-title":"Diabetes Res Clin Pract"},{"key":"5111_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.7381","author":"K Bonnesen","year":"2025","unstructured":"Bonnesen K, Heide-Jorgensen U, Christensen DH, Christiansen CF, Lash TL, Hennessy S, Matthews AA, Pedersen L, Thomsen RW, Schmidt M. Effectiveness of Empagliflozin vs Dapagliflozin for Kidney Outcomes in Type 2 Diabetes. JAMA Intern Med. 2025. https:\/\/doi.org\/10.1001\/jamainternmed.2024.7381.","journal-title":"JAMA Intern Med"},{"key":"5111_CR11","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/ckj\/sfx085","volume":"11","author":"L Friberg","year":"2018","unstructured":"Friberg L, Gasparini A, Carrero JJ. A scheme based on ICD-10 diagnoses and drug prescriptions to stage chronic kidney disease severity in healthcare administrative records. Clin Kidney J. 2018;11:254\u20138. https:\/\/doi.org\/10.1093\/ckj\/sfx085.","journal-title":"Clin Kidney J"},{"key":"5111_CR12","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.2337\/dc21-S011","volume":"44","author":"A American Diabetes","year":"2021","unstructured":"American Diabetes A. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S151\u201367. https:\/\/doi.org\/10.2337\/dc21-S011.","journal-title":"Diabetes Care"},{"key":"5111_CR13","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","volume":"98","author":"G Work","year":"2020","unstructured":"Kidney Disease: Improving Global Outcomes Diabetes, Work G. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98:S1\u2013115. https:\/\/doi.org\/10.1016\/j.kint.2020.06.019.","journal-title":"Kidney Int"},{"issue":"2","key":"5111_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/ehjcvp\/pvae094","volume":"11","author":"T Jimba","year":"2025","unstructured":"Jimba T, Kaneko H, Suzuki Y, Okada A, Azegami T, Ko T, Fujiu K, Morita H, Takeda N, Hayashi K, Yokoo T, Node K, Komuro I, Yasunaga H, Nangaku M, Takeda N. Effect of SGLT2i on kidney outcomes of individuals with type 2 diabetes according to body mass index: nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2025;11(2):155\u201363. https:\/\/doi.org\/10.1093\/ehjcvp\/pvae094.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"4","key":"5111_CR15","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/ndt\/gfaf197","volume":"41","author":"MJ Vargas-Brochero","year":"2026","unstructured":"Vargas-Brochero MJ, Russo I, Mazzierli T, Cara A, Berti GM, Milheiro J, Thongprayoon C, Allinovi M, Somma C, Raglianti V, D\u2019Arpino E, Zand L, Nu\u00f1ez-Delgado S, Soler MJ, Sethi S, Guti\u00e9rrez E, Praga M, Caravaca-Fontan F, Romagnani P, Fervenza FC. Antiproteinuric effect of SGLT2 inhibitors in non-diabetic glomerulopathies is dependent on body mass index. Nephrol Dial Transpl. 2026;41(4):703\u201314. https:\/\/doi.org\/10.1093\/ndt\/gfaf197.","journal-title":"Nephrol Dial Transpl"},{"key":"5111_CR16","unstructured":"E-Value Calculator [Internet]. Available from: https:\/\/www.evalue-calculator.com\/\/. Accessed 2\/2\/2025."},{"key":"5111_CR17","doi-asserted-by":"publisher","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268-274. https:\/\/doi.org\/10.7326\/M16-2607.","DOI":"10.7326\/M16-2607"},{"key":"5111_CR18","doi-asserted-by":"publisher","first-page":"e027762","DOI":"10.1161\/JAHA.123.027762","volume":"13","author":"Correction to","year":"2024","unstructured":"Correction to. Comparison of Effectiveness Among Different Sodium-Glucose Cotransporter-2 Inhibitors According to Underlying Conditions: A Network Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2024;13:e027762. https:\/\/doi.org\/10.1161\/JAHA.123.027762.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"5111_CR19","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1093\/ehjcvp\/pvae045","volume":"10","author":"A Engstr\u00f6m","year":"2024","unstructured":"Engstr\u00f6m A, S\u00f6derling J, Hviid A, Eliasson B, Gudbj\u00f6rnsdottir S, Wintzell V, Hveem K, Jonasson C, Melbye M, Pasternak B, Ueda P. Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study. Eur Heart J Cardiovasc Pharmacother. 2024;10(5):432\u201343. https:\/\/doi.org\/10.1093\/ehjcvp\/pvae045.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"7","key":"5111_CR20","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/ckj\/sfac044","volume":"15","author":"AYL Liu","year":"2022","unstructured":"Liu AYL, Low S, Yeoh E, Lim EK, Renaud CJ, Teoh STY, Tan GFL, Chai CC, Liu B, Subramaniam T, Sum CF, Lim SC. A real-world study on SGLT2 inhibitors and diabetic kidney disease progression. Clin Kidney J. 2022;15(7):1403\u201314. https:\/\/doi.org\/10.1093\/ckj\/sfac044.","journal-title":"Clin Kidney J"},{"key":"5111_CR21","unstructured":"United States Renal Data System. 2023 USRDS annual data report: epidemiology of kidney disease in the United States. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 2023."}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05111-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05111-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05111-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:47:42Z","timestamp":1787014062000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-05111-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5111"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-05111-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7586037\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was reviewed by the Institutional Review Board of Boston University (H-45693), which determined that the study did not constitute human subjects research and therefore did not require further ethical review. The requirement for informed consent was waived. This study adhered to the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"484"}}